Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Hypertension Receiving Bevacizumab for Breast Cancer
Recruiting · NCT02610413 · Observational (researchers observe without assigning treatment) · Lead sponsor: National Cancer Institute (NCI)
View the official record on ClinicalTrials.gov →Interventions studied
Laboratory Biomarker Analysis
What this trial is about
This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with hypertension receiving bevacizumab for breast cancer. Studying samples of germline DNA in the laboratory from patients with hypertension receiving bevacizumab for breast cancer may help doctors learn about changes that occur in DNA and identify biomarkers related to hypertension.
Who can take part
Age range
No age limits stated
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- European American patients with deoxyribonucleic acid (DNA) available and designated case or control
- Patients who developed grade 3-4 bevacizumab-induced hypertension during their treatment with bevacizumab
- Patients who did not develop hypertension following a full course of treatment with bevacizumab
Where it is running
1 location listed across 1 US state.
- Eastern Cooperative Oncology Group - Boston, Massachusetts, United States